



CardiNor AS and its partners Bioventix Ltd, Kaivogen Oy and Akershus University hospital have been granted Eurostars funding of € 631,000 for the Secretoneurin project

Oslo, Norway, March 5, 2018

CardiNor AS and its partners Bioventix Ltd, Kaivogen Oy and Akershus University hospital have been granted Eurostars funding of the project: ***Secretoneurin, a breakthrough blood biomarker for heart disease and Sudden Cardiac Arrest risk***. The total funding by EU is € 631,000. The Eurostars project will support the following important milestones for the company: Development and optimization of a simple test for measuring SN in the blood – Clinical validation using a very comprehensive patient material, this will also support and facilitate future CE marking – Optimization of assay production that will enable rapid commercialization.

More information can be found at: <https://cardinor.com/>.

For further information, please contact:

CardiNor AS

Dag Christiansen, CEO

Email: dag.chr@cardinor.com

Phone: +47-92254855

About CardiNor

CardiNor is a Norwegian Diagnostics company founded in 2015 with the purpose of fighting the Heart Failure (HF) pandemic, by leveraging the patented and exclusive rights to the commercial exploitation of Secretoneurin (SN), a blood-based biomarker that provides prognostic insights for several cardiovascular diseases (CVD). The team is focused on developing scalable cardiac biomarker tests to quantify the levels of SN in human blood, addressing a vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring.